Lilly’s tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
- Wednesday, December 9, 2020, 7:02
- Finance
- Add a comment
INDIANAPOLIS, Dec. 9, 2020 /PRNewswire/ — Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company’s (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the…
About the Author
adminasapcorp has written 41811 stories on this site.